Gland Pharma share news and announcements
NSE: GLANDBSE: 543245Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,850.40.
- Next results date: the board meets on 6 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹46,645 Cr261st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 41.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 May 2026
- 4.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 12.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 May 2026
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 4,23,05755.6% delivered
Gland Pharma analyst meets
255 filed, newest first. Page 1 of 6.
Oct 2026
21 Oct · Analysts
Sep 2026
10 Sep · Analysts
8 Sep · Analysts
4 Sep · Analysts
Aug 2026
31 Aug · Analysts
23 Aug · Analysts
10 Aug · Analysts
Jul 2026
24 Jul · Analysts
Jun 2026
22 Jun · Analysts
17 Jun · Analysts
16 Jun · Analysts
4 Jun · Analysts
May 2026
29 May · Analysts
26 May · Analysts
18 May · Analysts
Apr 2026
21 Apr · Analysts
Mar 2026
18 Mar · Analysts
13 Mar · Analysts
11 Mar · Analysts
9 Mar · Analysts
Feb 2026
25 Feb · Analysts
20 Feb · Analysts
18 Feb · Analysts
9 Feb · Analysts
1 Feb · Analysts
Jan 2026
9 Jan · Analysts
Dec 2025
12 Dec · Analysts
11 Dec · Analysts
8 Dec · Analysts
Nov 2025
13 Nov · Analysts
Oct 2025
31 Oct · Analysts
17 Oct · Analysts
Sep 2025
17 Sep · Analysts
8 Sep · Analysts
Aug 2025
25 Aug · Analysts
18 Aug · Analysts
13 Aug · Analysts
12 Aug · Analysts
Jul 2025
21 Jul · Analysts
Jun 2025
23 Jun · Analysts
19 Jun · Analysts
13 Jun · Analysts
9 Jun · Analysts
3 Jun · Analysts
2 Jun · Analysts
May 2025
20 May · Analysts
6 May · Analysts
Mar 2025
24 Mar · Analysts
11 Mar · Analysts
10 Mar · Analysts